1244 — 3D Medicines Income Statement
0.000.00%
Last trade - 00:00- HK$1.59bn
- HK$1.18bn
- CNY445.65m
- 15
- 15
- 53
- 13
Annual income statement for 3D Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Interim Report | ARS | ARS |
| Standards: | IFRS | IFRS | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 60.3 | 567 | 635 | 446 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 56 | 525 | 586 | 409 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 308 | 566 | 959 | 1,190 | 635 |
| Operating Profit | -308 | -505 | -392 | -555 | -190 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -635 | -1,462 | -1,052 | -562 | -199 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -635 | -1,462 | -1,052 | -563 | -199 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -635 | -1,434 | -1,024 | -525 | -183 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -635 | -1,434 | -1,024 | -525 | -183 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.47 | -5.51 | -3.89 | -2.3 | -0.704 |